Biohaven Ltd. (BHVN)
21.32
0.77 (3.75%)
At close: Apr 22, 2025, 3:28 PM
Company Description
Biohaven Ltd. is a clinical-stage biopharmaceutical company.
The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Biohaven Ltd.
| Country | United States |
| IPO Date | Sep 23, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 256 |
| CEO | Dr. Vladimir Coric M.D. |
Contact Details
Address: 215 Church Street New Haven, Connecticut United States | |
| Website | https://www.biohaven.com/ |
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001689813 |
| CUSIP Number | G11196105 |
| ISIN Number | VGG1110E1079 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman & Chief Executive Officer |
| Matthew Buten | Chief Financial Officer |
| Warren Volles J.D. | General Counsel & Chief Legal Officer |
| Clifford Bechtold M.S. | President, GM of Biohaven Ireland & Chief Compliance Officer |
| Deb Young | Senior Director of Regulatory Affairs & Operations |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| George C. Clark CPA | Vice President & Chief Accounting Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| John Tilton | Chief Commercial Officer of Rare Diseases |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | DEFA14A | Filing |
| Mar 18, 2025 | DEF 14A | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4/A | [Amend] Filing |
| Mar 03, 2025 | 8-K | Current Report |
| Mar 03, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |